GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Cyclically Adjusted PB Ratio

AMRN (Amarin) Cyclically Adjusted PB Ratio : 0.72 (As of May. 29, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Amarin's current share price is $11.49. Amarin's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $15.96. Amarin's Cyclically Adjusted PB Ratio for today is 0.72.

The historical rank and industry rank for Amarin's Cyclically Adjusted PB Ratio or its related term are showing as below:

AMRN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.5   Med: 3.55   Max: 324
Current: 0.71

During the past years, Amarin's highest Cyclically Adjusted PB Ratio was 324.00. The lowest was 0.50. And the median was 3.55.

AMRN's Cyclically Adjusted PB Ratio is ranked better than
79.76% of 677 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs AMRN: 0.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amarin's adjusted book value per share data for the three months ended in Mar. 2025 was $22.864. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.96 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amarin Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Amarin's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Cyclically Adjusted PB Ratio Chart

Amarin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 18.18 3.29 1.54 0.65

Amarin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.46 1.05 0.90 0.65 0.56

Competitive Comparison of Amarin's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Amarin's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amarin's Cyclically Adjusted PB Ratio falls into.


;
;

Amarin Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Amarin's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=11.49/15.96
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amarin's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Amarin's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=22.864/123.4051*123.4051
=22.864

Current CPI (Mar. 2025) = 123.4051.

Amarin Quarterly Data

Book Value per Share CPI Adj_Book
201506 -12.302 100.573 -15.095
201509 -14.778 100.274 -18.187
201512 -16.567 99.676 -20.511
201603 -19.573 99.676 -24.233
201606 -20.457 101.072 -24.977
201609 -0.683 100.274 -0.841
201612 -2.482 99.676 -3.073
201703 -3.926 100.374 -4.827
201706 -4.662 100.673 -5.715
201709 -5.203 100.474 -6.391
201712 -6.602 100.075 -8.141
201803 -2.795 100.573 -3.430
201806 -4.834 101.072 -5.902
201809 -4.912 101.371 -5.980
201812 8.008 100.773 9.807
201903 7.201 101.670 8.740
201906 7.681 102.168 9.278
201909 32.113 102.268 38.750
201912 32.569 102.068 39.377
202003 31.182 102.367 37.590
202006 30.873 101.769 37.437
202009 30.956 101.072 37.796
202012 31.972 101.072 39.037
202103 32.152 102.367 38.760
202106 32.656 103.364 38.988
202109 32.480 104.859 38.225
202112 33.641 106.653 38.925
202203 32.303 109.245 36.490
202206 29.196 112.779 31.947
202209 29.113 113.504 31.653
202212 29.447 115.436 31.480
202303 28.718 117.609 30.133
202306 27.889 119.662 28.761
202309 27.078 120.749 27.674
202312 27.009 120.749 27.603
202403 26.583 120.990 27.114
202406 26.848 122.318 27.087
202409 25.841 121.594 26.226
202412 23.625 122.439 23.811
202503 22.864 123.405 22.864

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amarin  (NAS:AMRN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Amarin Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Amarin's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin Business Description

Traded in Other Exchanges
Address
One Central Plaza, 36 Dame Street, 5th Floor, Dublin, IRL, 02
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Executives
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3